Francesco Micheli Net Worth

The estimated Net Worth of Francesco Micheli is at least $465 Million dollars as of 13 August 2020. Francesco Micheli owns over 1,500,000 units of Intercept Pharmaceuticals Inc stock worth over $76,000,000 and over the last 11 years Francesco sold ICPT stock worth over $389,440,658.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Francesco Micheli ICPT stock SEC Form 4 insiders trading

Francesco has made over 7 trades of the Intercept Pharmaceuticals Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Francesco sold 1,500,000 units of ICPT stock worth $71,250,000 on 13 August 2020.

The largest trade Francesco's ever made was selling 1,500,000 units of Intercept Pharmaceuticals Inc stock on 13 August 2020 worth over $71,250,000. On average, Francesco trades about 690,550 units every 356 days since 2013. As of 13 August 2020 Francesco still owns at least 4,000,000 units of Intercept Pharmaceuticals Inc stock.

You can see the complete history of Francesco Micheli stock trades at the bottom of the page.

What's Francesco Micheli's mailing address?

Francesco's mailing address filed with the SEC is Via Privata Giovannino De Grassi, 11, 20123 Milano MI, Italy.

Insiders trading at Intercept Pharmaceuticals Inc

Over the last 12 years, insiders at Intercept Pharmaceuticals Inc have traded over $1,530,243,701 worth of Intercept Pharmaceuticals Inc stock and bought 2,408,920 units worth $77,118,364 . The most active insiders traders include Srinivas Akkaraju, Jonathan Silverstein, and Francesco Micheli. On average, Intercept Pharmaceuticals Inc executives and independent directors trade stock every 10 days with the average trade being worth of $1,114,673. The most recent stock trade was executed by Srinivas Akkaraju on 10 March 2021, trading 237,000 units of ICPT stock currently worth $5,017,290.

What does Intercept Pharmaceuticals Inc do?

we are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (pbc), nonalcoholic steatohepatitis (nash), primary sclerosing cholangitis (psc) and biliary atresia. in a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. we are committed to improving patients’ lives and addressing the liver community’s most pressing needs. our corporate headquarters is located in new york, and we have additional offices in san diego, london and perugia. for more information about intercept, please visit our website at: www.interceptpharma.com and follow us on twitter at: @interceptpharma.

Complete history of Francesco Micheli stock trades at Intercept Pharmaceuticals Inc

Intercept Pharmaceuticals Inc executives and stock owners

Intercept Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Mark Pruzanski,
  President, Chief Executive Officer, Director
• Jerome Durso,
  Chief Operating Officer
• Ryan Sullivan,
  General Counsel, Secretary
• Richard Kim,
  President, U.S. Commercial & Strategic Marketing
• Sandip Kapadia,
  Chief Financial Officer, Treasurer
• Gail Cawkwell,
  Senior Vice President - Medical Affairs, Safety & Pharmacovigilance
• Lisa Bright,
  President, International
• David Ford,
  Chief Human Resource Officer
• Dr. Mark Pruzanski M.D.,
  Founder, Advisor & Director
• Jerome B. Durso,
  Pres, CEO & Director
• Paolo Fundaro,
  Independent Chairman of the Board
• Gino Santini,
  Lead Independent Director
• Glenn Sblendorio,
  Independent Director
• Daniel Welch,
  Independent Director
• Daniel Bradbury,
  Independent Director
• Luca Benatti,
  Independent Director
• Nancy Miller-Rich,
  Independent Director
• Keith Gottesdiener,
  Independent Director
• Srinivas Akkaraju,
  Independent Director
• Jason Campagna,
  Chief Medical Officer
• Christian Weyer,
  Executive Vice President - Research & Development
• Linda M. Richardson,
  Exec. VP & Chief Commercial Officer
• Jared M. Freedberg J.D.,
  Gen. Counsel
• Lisa M. DeFrancesco,
  Sr. VP of Corp. Affairs & Investor Relations
• Rocco Venezia,
  Chief Accounting Officer & Treasurer
• Bryan Ball,
  Chief Quality Officer & Sr. VP of Operations
• Andrew Saik,
  Chief Financial Officer
• Barbara Gayle Duncan,
  Chief Financial Officer
• Rachel Mc Minn,
  Chief Strategy Officer
• David Shapiro,
  Chief Medical Officer
• Linda M Richardson,
  EVP & Chief Commercial Officer
• S.P.A. Genextra,
  
• M Michelle Berrey,
  President, R&D and CMO
• Daniel Paul Regan,
  Chief Commerical Officer
• Jonathan Silverstein,
  Director
• Advisors Llc Orbi Med Capit...,
  
• Lorenzo Tallarigo,
  Director
• Klaus R Dr Veitinger,
  Director
• Sanj K Patel,
  Director
• Luciano Adorini,
  Chief Scientific Officer
• Nicole Williams,
  Director
• Francesco Micheli,
  
• Bryan Ball,
  Chief Qual. Officer & SVP Ops.
• Rocco Venezia,
  Chief Accounting Officer
• Dagmar Rosa Bjorkeson,
  Director
• Lisa De Francesco,
  SVP, IR & Corp. Affairs
• Jared Freedberg,
  General Counsel